Newark-based Intabio, a developer of biotherapeutics technology, announced on Tuesday that it had raised $9.5M in a Series A funding round. The funding was led by Northpond Ventures, and also included Genoa Ventures and Vertical Venture Partners. Intabio said the new funding comes on top of an earlier $3.2M seed funding it raised in 2017. Intabio says it is developing a comprehensive analysis of antibody and protein biopharmaceutical products to help biopharma companies meet the accelerated timelines required for breakthrough therapy applications.
posted on Tuesday, October 30, 2018 Related companies: Intabio, Inc. Related stories: > Prismatic Finds $15M For Personalized News > PocketMath Finds $10M > Eventbrite Finds $6.46M > Drawbridge Finds $6.5M > indeni Finds $10M silicontap.com Home